Trials / Withdrawn
WithdrawnNCT00382837
Study of Epratuzumab in Systemic Lupus Erythematosus
A Phase III Multi-Center, OpenLabel, Follow-Up Study to Assess the Safety & Efficacy of Epratuzumab in Patients With Acute Severe SLE Flares Excluding the Renal or Neurologic Systems
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epratuzumab |
Timeline
- Start date
- 2007-01-01
- First posted
- 2006-10-02
- Last updated
- 2014-05-21
Locations
54 sites across 13 countries: United States, Belgium, Brazil, Canada, Czechia, France, Germany, Hungary, Italy, Netherlands, Slovakia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00382837. Inclusion in this directory is not an endorsement.